MarketInOut Stock Screener Log In | Sign Up
 

Genmab A/S ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 09/18/2026
Genmab A/S ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization20,999 mln
Float607 mln
Earnings Date11/05/2026

EPS

1.32
Moderate

P / E

26.32
Elevated

Piotroski F-Score

5 / 9
Neutral

Beneish M-Score

-2.76
Likely reliable

1-Year Forecast

39.14
Modest upside

Relative Strength

80 / 100
Strongly outperforming

Business Description

Founded in Denmark in 1998, Genmab is a biotechnology company focused on developing antibody-based treatments for cancer and other serious diseases. Its commercial portfolio includes therapies for blood cancers such as multiple myeloma and lymphoma, cervical cancer, thyroid eye disease, multiple sclerosis, and other conditions, with several more treatments in various stages of development targeting solid tumors, blood disorders, and additional cancer types. The company works alongside a broad network of partners, including Johnson & Johnson, Pfizer, AbbVie, Amgen, and BioNTech, among others.

Key Fundamentals

EPS1.32
P/E26.32
ROE13.77
RPS6.71
ROIC15.87
ROA7.67
Interest Cover4.93
EBITDA, mln1,269
EV / EBITDA19.22
EV / EBIT20.76
Revenue, mln4,131
EV / Revenue5.90

Quote Details

Last 34.74
Change 0.21 (0.61%)
Open 34.92
Volume 2,711,559
Turnover 94,199,568
Average Volume 2,227,390

Financial Ratios

Pre-Tax Profit Margin22
Leverage Ratio2.10
Current Ratio2.46
Price / Book3.43
Price / Cash Flow23.73
Price / Free Cash Flow24.32
Debt / Equity0.89
Price / Sales5.09
PEG Ratio1.61

Financial Strength

Altman Z-Score3.16
Piotroski F-Score 5 / 9
Beneish M-Score-2.76
Price to Intrinsic Value1.23
Price to Lynch Fair Value1.01
1-Year Target Price39.14
Shiller PE Ratio31.60
Short Ratio2.40
Short % of Float1.12

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 6.99% 92 / 100   
1 Month 1.85% 80 / 100   
2 Months 37.64% 94 / 100   
6 Months 35.02% 89 / 100   
1 Year 23.72% 79 / 100   



Disclaimer - Privacy Policy - Terms Of Service - Cookie Use Policy - FAQ - Contact Us